1h Free Analyst Time
PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2020-2024Speak directly to the analyst to clarify any post sales queries you may have.
The parp (Poly ADP-ribose Polymerase) inhibitors market is poised to grow by $ 810.23 million during 2020-2024 progressing at a CAGR of 12% during the forecast period. The reports on parp (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors and increasing patient assistance programs. In addition, expanded application of PARP inhibitors is anticipated to boost the growth of the market as well.
The parp (Poly ADP-ribose Polymerase) inhibitors market analysis includes end-user segment and geographic landscapes.
The parp (Poly ADP-ribose Polymerase) inhibitors market is segmented as below:
By End-User
- Ovarian cancer
- Breast cancer
- Others
By Geographic Landscapes
- North America
- Europe
- APAC
- South America
- MEA
This study identifies the ease of administration as one of the prime reasons driving the parp (Poly ADP-ribose Polymerase) inhibitors market growth during the next few years.
The parp (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:
- Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
- Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
- Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-ribose Polymerase) inhibitors market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the parp (Poly ADP-ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by End-user
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global parp (poly adp-ribose polymerase) inhibitors market: AbbVie Inc., AstraZeneca Plc, Bayer AG, Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is ease of administration."
According to the report, one of the major drivers for this market is the expanded application of PARP inhibitors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- AstraZeneca Plc
- Bayer AG
- Clovis Oncology Inc.
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Jiangsu Hengrui Medicine Co. Ltd.
- Johnson & Johnson
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
